Joint research project „Added value in regenerative medicine – a pioneering approach to facilitate translation“

The foundation of the RTC is based on the joint research project “Added value in regenerative medicine”which is funded for four years. It has two goals:

1) Fostering the continued development of cardiac stem cell therapies so that they can be applied as standardised treatments of high quality to patients showing appropriate indications. This requires proof of efficacy and safety of the therapy in accordance with all relevant regulations and guidelines by means of clinical studies and parallel research projects.

2) Standardisation of the translational process. According to the latest legal situation, treatments with stem cells belong to the “Advanced Therapy Medicinal Product ”. The essential transfer process from basic research to the launch of stem cell therapy as a novel drug or treatment method ( translation) is virgin territory for scientists, as well as industry and licensing authorities. Using the example of cardiac stem cell therapy, the RTC will work closely with all relevant authorities to define standards which offer a maximun of quality and safety for patients. In addition, information regarding the translational process will be made available (link zu Translation). Further research and development projects in the field of regenerative medicine will directly benefit from the accumulated know-how and technologies. The RTC will offer trainings and seminars for prospective users of the standardised stem cell therapies.